Group items tagged

As we take look back over the past year and reflect on what we have achieved, it's also important that we look ahead to new challenges and opportunities that may arise in 2023. We have seen remarkable innovation across the industry in 2022, from big break throughs in treatment and improvements to patient outcomes, to how the industry is working with big data and technology. But it's fair to say that these achievements came paired with just as many challenges including a continued talent shortage, hangovers from the pandemic, increasing pressures to innovate and ongoing macroeconomic challenges. As we head into 2023, I expect these existing challenges to continue alongside new ones, but I also anticipate more opportunities to present themselves. At Pharamanovia, we predict that the key trends set to catalyse the pharmaceutical and healthcare industries in 2023 include break through innovations, technology, big data, sustainability, ongoing policy changes and a shift in investment due to inflation. Utilising big data and tech Technology has been recognised as one of the industry's biggest tools for many years, and I don't expect to see the pace of how we use technology in healthcare and pharma to slow down any time soon. In 2023, I expect that we will see further automation in the way we work, with an increase in digital engagement and healthcare providers leveraging remote access further.

"The UK remains genuinely world-leading for life sciences in numerous areas - yet we continue to underperform on our potential," said Richard Torbett, Chief Executive of the Association of the British Pharmaceutical Industry (ABPI). His statement is based on recent government data indicating that the UK is not fully capitalizing on its strong historical and institutional advantages in life sciences across a range of economic, health, and research indicators. The latest 'Life sciences competitiveness indicators 2024' report from the government's Office for Life Sciences revealed that while the pharmaceutical industry leads in R&D spending with £9 billion in 2022, representing a fifth of total business investment, the country saw a notable decline in foreign direct investment (FDI), industry clinical trials, and exports. In 2023, FDI dropped by 21 per cent to £0.8 billion, following a trend that saw a 52 per cent decrease over the previous two years, including a £0.9 billion fall in FDI the year prior.

The International Pharmaceutical Federation (FIP) has released a handbook today (February 23) on guidance for pharmacists on supporting self-care. The handbook, "Empowering self-care: A handbook for pharmacists", covers six areas of self-care - sore throat, gastrointestinal complaints, musculoskeletal pain, fever in children, sexual health and disinfection. Commenting on the release, Rúben Viegas, co-author of the handbook, said: Community pharmacists already help people in self-care by giving advice on non-prescription medicines, nutrition, physical activity and lifestyle choices, but this new resource from FIP offers added support for these professional services that demonstrate our profession's commitment to primary health care." The publication, also intended as an advocacy resource for FIP's member organisations, discusses latest trends and strategies in self-care and explores innovations adopted across several practice areas. It aims to provide pharmacists with concise guidance on coaching practices and person-centred approaches to promote self-care.

In its response to a Freedom of Information Request (FOI), the NHS Business Services Authority (NHSBSA) has confirmed a net decrease of 101 pharmacies in England - with 371 closures and 270 new contracts. Meanwhile, the General Pharmaceutical Council data projected a drop of 43 registered pharmacies in England, Wales, and Scotland for the year ending March 31, 2023, compared to the preceding period. The data, released by business advisor Christie & Co in its annual pharmacy market review on Sept. 5, revealed a total of 14,328 pharmacies across all four UK country regions as of March 31, 2023, indicating a 0.3 per cent decrease from the previous year. Corporate operators experienced a net reduction of 249 pharmacies, while the total number of independent operators remained consistent with 2022. According to the study, the corporate sector saw the most substantial shift, with a 13.7 per cent reduction in businesses operating 300 or more pharmacies. Following closely, groups managing 11 to 15 pharmacies experienced a 5.6 per cent decrease. Christie & Co attributed this shift in group size to operators acquiring additional pharmacies through corporate disposal opportunities throughout the year.

The Pharmacists' Defence Association (PDA) has expressed concerns over Boots UK's decision to reduce supplemental opening hours at some pharmacies. The association stated: "Some pharmacists and other staff at Boots are being notified this week of changes to opening hours at their place of work, with local briefings taking place. The PDA are supporting their members to deal with any potential impact on their employment." It said that reducing pharmacy opening hours would affect patients' access to a trusted healthcare professional, especially if it is being done by the largest community pharmacy multiple. It even called upon the NHS to adequately fund community pharmacies to ensure they remain open when patients and local communities need their services. Meanwhile, Boots management has informed PDA that most of its employees are not pharmacists, and "less pharmacists are expected to be directly impacted by these changes than other colleagues," PDA said.

The Royal Pharmaceutical Society (RPS) is seeking views of pharmacists to help shape the future of pharmacy practice in England over the next decade. The RPS's project with The King's Fund, transforming pharmacy practice, aims to develop a vision for the role of pharmacists and pharmacy teams working across systems, providing patient care and NHS services. It's due to be published at the end of the year. "From 15 August to 30 September we are asking people to respond to our consultation on six key themes," the RPS said. "We'll also be holding face-to-face and virtual events in September to hear your views." The King's Fund has completed a literature review which has helped inform the initial six themes which will be the focus of the consultation, all of which can be downloaded and read before responding.

The Royal Pharmaceutical Society (RPS) has been on the lookout for innovative ideas and suggestions that could transform the future of pharmacy practice in England over the next decade. The society's new project with the King's Fund to transform the future of pharmacy practice in England is at a consultation phase, seeking views and opinions of pharmacy teams from all areas of practice including primary, secondary, social and community care to ensure that the system gets the best out of pharmacy and the public receives seamless, joined-up care. "We want to build a vision that sets out the role of and value of pharmacists and pharmacy teams working across systems, providing patient care and NHS services," said RPS in a statement. "Transforming the future of pharmacy practice recognises the urgent need to build on new ways of working established across health and care systems during the pandemic to meet the increasingly complex health needs of people and improve patient outcomes."